Gentamicin

Gentamicin

Systematic (IUPAC) name
(3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6- diamino-3-{[(2R,3R,6S)- 3-amino-6-[(1R)- 1-(methylamino)ethyl]oxan-2-yl]oxy}- 2-hydroxycyclohexyl]oxy}-5-methyl- 4-(methylamino)oxane-3,5-diol
Clinical data
Trade names	Cidomycin, Septopal, Genticyn, Garamycin, others
AHFS/Drugs.com	monograph
MedlinePlus	a682275
Pregnancy category	D
Legal status	UK: POM (Prescription only)
Routes of administration	IV, eye drop, IM, topical
Pharmacokinetic data
Bioavailability	limited oral bioavailability
Protein binding	0-10%
Biological half-life	2 hrs
Excretion	renal
Identifiers
CAS Number	1403-66-3 Y
ATC code	D06AX07 (WHO) J01GB03 S01AA11 S02AA14 S03AA06 QA07AA91 (WHO) QG01AA91 (WHO) QG51AA04 (WHO) QJ51GB03 (WHO)
PubChem	CID: 3467
IUPHAR/BPS	2427
DrugBank	DB00798 N
ChemSpider	390067 Y
UNII	T6Z9V48IKG Y
KEGG	D08013 Y
ChEBI	CHEBI:27412 Y
ChEMBL	CHEMBL195892 Y
Chemical data
Formula	C21H43N5O7
Molecular mass	477.596 g/mol
SMILES O[C@]3(C)[C@H](NC)[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]1O[C@H](C(NC)C)CC[C@H]1N)[C@@H]2O)OC3
InChI InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1 Y Key:CEAZRRDELHUEMR-URQXQFDESA-N Y
NY (what is this?)  (verify)

Gentamicin, sold under brand names Garamycin among others, is an antibiotic used to treat many types of bacterial infections. This may include bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. It is not effective for gonorrhea or chlamydia infections. It can be given intravenously, by injection into a muscle, or topically. Topical formulations may be used in burns or for infections of the outside of the eye. In the developed world it is often only used for two days until bacterial cultures determine what antibiotics the infection is sensitive to. The dose required should be monitored by blood testing.

Gentamicin can cause inner ear problems and kidney problems. The inner ear problems can include problems with balance and problems with hearing. These problems may be permanent. If used during pregnancy it can cause harm to the baby. It appears to be safe for use during breastfeeding. Gentamicin is a type of aminoglycoside. It works by stopping the bacteria from making protein which typically kills the bacteria.

Gentamicin was discovered in 1963. It is made from the bacteria Micromonospora purpurea. Gentamicin is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. It is available as a generic medication. It wholesale cost is between 0.05 and 0.58 USD per day.

Medical uses

Active against a wide range of bacterial infections, mostly Gram-negative bacteria including Pseudomonas, Proteus, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Serratia, and the Gram-positive Staphylococcus. Gentamicin is used in the treatment of respiratory tract infections, urinary tract infections, blood, bone and soft tissues infections of these susceptible bacteria.

Gentamicin is not used for Neisseria gonorrhoeae, Neisseria meningitidis or Legionella pneumophila bacterial infections (because of the risk of the person going into shock from lipid A Endotoxin found in certain Gram-negative organisms). Gentamicin is also useful against Yersinia pestis, its relatives, and Francisella tularensis (the organism responsible for Tularemia seen often in hunters and/or trappers).

Some Enterobacteriaceae, Pseudomonas spp., Enterococci, Staphylococcus aureus and other Staphylococci are resistant to gentamicin sulfate, to varying degrees.

Side effects

Side effects of gentamicin can range from less severe reactions such as nausea and vomiting to more severe reactions such as:

• Low blood counts
• Allergic responses
• Neuromuscular problems
• Nerve damage
• Kidney damage (nephrotoxicity)
• Ear disorders (ototoxicity)

Nephrotoxicity and ototoxicity are thought to be dose related with higher doses causing greater chance of toxicity. These two toxicities may have delayed presentation, sometimes not appearing until after completing treatment.

Kidney damage

Kidney damage is a problem in 10-25% of people who receive aminoglycosides, and gentamicin is one of the most nephrotoxic of the class. Oftentimes acute nephrotoxicity is reversible, but it may be fatal. The risk of nephrotoxicity can be affected by the dose, frequency, duration of therapy, and concurrent use of certain medications such as NSAIDs, diuretics, cisplatin, cyclosporin, cephalosporin, amphotericin, iodide contrast media, and vancomycin.

Factors that increase risk of nephrotoxicity include:

• Increased age
• Reduced renal function
• Pregnancy
• Hypothyroidism
• Hepatic dysfunction
• Volume depletion
• Metabolic acidosis
• Sodium depletion

Kidney dysfunction is monitored by measuring creatinine in the blood, electrolyte levels, low urine output, foamy urine, and concentrations of other chemical in the blood.

Inner ear

11% of the population who receives aminoglycosides experience damage to their inner ear. The common symptoms of inner ear damage are: tinnitus, hearing loss, vertigo, trouble with coordination, dizziness. Chronic use of gentamicin can affect two area of the ears. First, damage of the inner ear hair cells can result in irreversible hearing loss. Second, damage to inner ear vestibular apparatus can lead to balance problems. To reduce the risk of ototoxicity it is recommended to stay hydrated.

Factors that increase risk of inner ear damage include:

• High blood uric acid levels
• Kidney dysfunction
• Liver dysfunction
• Higher doses
• Long courses of therapy
• Elderly
• Also taking strong diuretics (e.g. furosemide)

Mechanism of action

Gentamicin is a bactericidal antibiotic that works by irreversibly binding the 30S subunit of the bacterial ribosome, interrupting protein synthesis. This mechanism of action is similar to other aminoglycosides.

Components

Gentamicin is composed of a number of related gentamicin components and fractions which have varying degrees of antimicrobial potency. The main components of gentamicin include members of the gentamicin C complex: gentamicin C1, gentamicin C1a, and gentamicin C2 which compose approximately 80% of gentamicin and have been found to have the highest antibacterial activity. Gentamicin A, B, X, and a few others make up the remaining 20% of gentamicin and have lower antibiotic activity than the gentamicin C complex. The exact composition of a given sample or lot of gentamicin is not well defined, and the level of gentamicin C components or other components in gentamicin may differ from lot-to-lot depending on the gentamicin manufacturer or manufacturing process. Because of this lot-to-lot variability, it can be difficult to study various properties of gentamicin including pharmacokinetics and microorganism susceptibility if there is an unknown combination of chemically related but different compounds.

Contraindications

Gentamicin should not be used if a person has a history of hypersensitivity such as anaphylaxis shock or other serious toxic reaction to gentamicin or any other Aminoglycosides.

Special Populations

Pregnancy and breastfeeding

Gentamicin is not recommended in pregnancy unless the benefits outweigh the risks for the mother. Gentamicin can cross the placenta and several reports of irreversible bilateral congenital deafness in children have been seen. Intramuscular injection of gentamicin in mothers can cause muscle weakness in the newborn.

The safety and efficacy for gentamicin in nursing mothers has not been established. Detectable gentamicin levels are found in human breast milk and in nursing babies.

Geriatrics

Renal function should be assessed before beginning therapy and during in elderly due to a decline in glomerular filtration rate. This population can have longer than usual gentamicin levels in the body. Use cautiously in persons with renal, auditory, vestibular, or neuromuscular dysfunction.

Pediatrics

Gentamicin may not be appropriate to use in children, including newborns and infants. Studies have shown higher serum levels and a longer half-life in this population. Check renal function periodically during therapy. Hypocalcemia, hypokalemia, and muscle weakness have been reported after gentamicin injection.

History

Gentamicin for injection

Gentamicin is produced by the fermentation of Micromonospora purpurea. It was discovered in 1963 by Weinstein, Wagman et al. at Schering Corporation in Bloomfield, N.J. working with source material (soil samples) provided by Rico Woyciesjes. Subsequently it was purified and the structures of its three components determined by Cooper, et al., also at the Schering Corporation. It was initially used as a topical treatment for burns at the Atlanta and San Antonio burn units and was introduced into IV usage in 1971. It remains a mainstay for use in sepsis.

It is synthesized by Micromonospora, a genus of Gram-positive bacteria widely present in the environment (water and soil). To highlight their specific biological origins, gentamicin and other related antibiotics produced by this genus (verdamicin, mutamicin, sisomicin, netilmicin, retymicin) generally have their spellings ending in ~micin and not in ~mycin.

Research

Gentamicin is also used in molecular biology research as an antibacterial agent in tissue and cell culture, to prevent contamination of sterile cultures. Gentamicin is one of the few heat-stable antibiotics that remain active even after autoclaving, which makes it particularly useful in the preparation of some microbiological growth media.